Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?

The question patients ask first, usually within a few minutes of any clinical conversation about GLP-1 medications, is the comparison one. Tirzepatide or semaglutide? Which is better? The honest answer requires a small amount of patience with the trial design — and a willingness to accept that "better" depends on what is being optimised for.

The headline numbers favour tirzepatide. At 72 weeks in the SURMOUNT-1 obesity trial, participants on the highest dose lost an average of 20.9% of body weight, compared with 14.9% on semaglutide at 68 weeks in STEP 1. That gap is real and substantial. The trials were similar enough in design to make the comparison meaningful, though they were not run head-to-head. The fuller picture — side effects, mechanism, access, cost, tolerability for individual patients — is where the comparison becomes more interesting.

The mechanism difference

Semaglutide is a single-receptor agonist. It activates the GLP-1 receptor, mimicking the action of the gut hormone of the same name. The mechanism is well-characterised: slowed gastric emptying, enhanced insulin response to glucose, reduced glucagon, and — through GLP-1 receptors in the central nervous system — reduced appetite and modulated reward response to food cues.

Tirzepatide is a dual-receptor agonist. It activates both the GLP-1 receptor and the GIP receptor — glucose-dependent insulinotropic polypeptide, another incretin hormone whose role in metabolism has been studied for decades but whose pharmacological utility was less obvious until tirzepatide demonstrated it. The addition of GIP signalling appears to enhance insulin sensitivity, alter lipid metabolism, and — through mechanisms that are still being clarified — amplify the weight loss effect beyond what GLP-1 agonism alone produces.

Whether GIP agonism, antagonism, or some context-dependent combination is the active mechanism remains a point of debate in incretin biology — but the clinical outcome is clear: the dual agonist outperforms the mono agonist on weight loss endpoints, across populations.

The numbers from the major trials

STEP 1, led by John Wilding at the University of Liverpool, randomised 1,961 adults with obesity (mean BMI 38) to semaglutide 2.4mg weekly or placebo for 68 weeks. Mean weight loss on semaglutide was 14.9%, compared with 2.4% on placebo. About one-third of participants lost at least 20% of body weight.

SURMOUNT-1, led by Ania Jastreboff at Yale, randomised 2,539 adults with obesity (mean BMI 38) to tirzepatide 5mg, 10mg, 15mg, or placebo for 72 weeks. Mean weight loss on the highest dose was 20.9%; on the middle dose, 19.5%; on the lowest, 15%. About 57% of participants on the 15mg dose lost at least 20% of body weight — roughly double the proportion seen in STEP 1.

The only direct head-to-head comparison published to date is SURPASS-2, a 40-week trial in adults with type 2 diabetes (not obesity primarily), led by Juan Frías at the National Research Institute in Los Angeles. Tirzepatide at all three doses produced greater HbA1c reduction and greater weight loss than semaglutide 1mg weekly. The comparison is informative but limited: it used a lower semaglutide dose than the 2.4mg used for obesity, and the patient population had diabetes rather than obesity as the primary indication. A head-to-head obesity comparison at maximum doses has not been published.

The reasonable inference from the available data: tirzepatide at maximum dose produces greater weight loss than semaglutide at maximum dose, by approximately five to six percentage points on average. The individual range is wide in both cases.

Side effects: similar profile, slightly different intensity

Both medications produce predominantly gastrointestinal side effects — nausea, diarrhoea, constipation, vomiting — most concentrated during dose escalation and improving with adaptation. The profiles are similar enough that a patient who tolerates one tends to tolerate the other; a patient who struggles with one often struggles with the other for the same mechanistic reason.

Tirzepatide's trial data shows modestly higher rates of GI adverse events at maximum dose, consistent with its more potent appetite-suppressing effect. Discontinuation rates due to adverse events were 4.3% on the 15mg tirzepatide dose in SURMOUNT-1, compared with 7.0% on semaglutide in STEP 1 — though direct comparison across trials is hazardous given different populations and titration schedules.

The clinical experience reported by obesity medicine specialists is that the medications feel similar to patients in the first weeks of treatment, with the differences emerging at maintenance doses where tirzepatide's stronger effect on appetite is more apparent.

Specific safety notes shared between both

Both medications carry boxed warnings about thyroid C-cell tumours based on rodent studies, with the contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Both have been associated with rare cases of pancreatitis. Both can affect oral medication absorption due to slowed gastric emptying — relevant for oral contraceptives, certain antibiotics, and timed-release formulations. The safety profiles are not identical but they are closely parallel.

Cost, access, and the practical reality in 2026

Branded semaglutide for obesity is sold under the name Wegovy; the same molecule at lower doses for type 2 diabetes is sold as Ozempic. Branded tirzepatide for obesity is Zepbound; for diabetes it is Mounjaro. List prices in the United States as of 2026 sit in the range of $1,000–$1,400 per month for both, though manufacturer programmes, telehealth bundles, and the increasing competitiveness of the market have brought effective patient costs down considerably from 2023–2024 levels.

Insurance coverage remains the dominant variable. Coverage for obesity indications is narrower than for diabetes, varies by employer plan, and typically requires prior authorisation with documented BMI thresholds and comorbidities. Telehealth providers have created alternative pathways that work for patients whose coverage is limited.

Compounded semaglutide and compounded tirzepatide became widely available during shortages in 2023–2024; both are now under tighter FDA regulatory pressure, and the long-term role of compounded options is in flux. The current guidance from obesity medicine professional societies is to prefer branded products where access permits.

Who each one tends to suit

This is where the comparison stops being a contest. The medications are sufficiently similar in mechanism and side effect profile that the choice usually comes down to access, insurance coverage, and individual response.

Tirzepatide tends to be the choice when:

• Maximum weight loss is the priority and the patient has a high BMI or significant comorbidity burden.
• Type 2 diabetes coexists — the metabolic effects of dual GIP/GLP-1 agonism are advantageous.
• The patient has tried semaglutide and not achieved sufficient weight loss at maximum dose.
• Insurance covers tirzepatide preferentially.

Semaglutide tends to be the choice when:

• The cardiovascular benefit data is the priority — semaglutide has a more extensive outcomes evidence base (SELECT trial), with established reduction in major adverse cardiovascular events.
• Insurance covers semaglutide preferentially.
• The patient prefers a longer track record; semaglutide has been on the market for obesity since 2021, tirzepatide for obesity since late 2023.
• Tirzepatide is unavailable due to local supply or formulary restrictions.

For many patients, the practical question is not which medication is theoretically better but which one their insurance will pay for, which one their clinician is comfortable prescribing, and which one they can get reliably. Both are excellent options. Neither will work optimally without attention to the other variables — nutrition, resistance training, sleep, and the long-term framing of obesity as a chronic disease requiring ongoing treatment rather than a temporary intervention.

What the next few years are likely to bring

The pipeline beyond tirzepatide includes triple agonists targeting GLP-1, GIP, and glucagon receptors (retatrutide, with phase 2 data showing weight loss in the 24% range at 48 weeks), oral formulations of both semaglutide and emerging compounds, and combinations with other mechanisms. The trajectory is toward more options rather than fewer, with the field gradually identifying which mechanism combinations suit which patients.

The current choice between semaglutide and tirzepatide will likely remain the most common one for the next several years. The honest comparison is that one is somewhat stronger on weight loss, the other has a longer evidence base and slightly different access patterns, and the difference between them is smaller than the difference between either of them and not treating obesity at all.

Key takeaways

• SURMOUNT-1: tirzepatide 15mg produced 20.9% mean weight loss at 72 weeks. STEP 1: semaglutide 2.4mg produced 14.9% at 68 weeks. The trials weren't head-to-head but were broadly comparable.
• SURPASS-2 (in diabetes, with lower semaglutide dose) is the only direct head-to-head and favoured tirzepatide.
• Mechanism: semaglutide is a GLP-1 mono agonist; tirzepatide is a GLP-1/GIP dual agonist, which appears to drive the greater weight loss.
• Side effect profiles are similar in kind, with tirzepatide modestly more intense at maximum dose, consistent with its stronger pharmacological effect.
• Semaglutide has more extensive cardiovascular outcomes data (SELECT trial); tirzepatide's CV outcomes trials are ongoing.
• For most patients in 2026, the choice is driven by insurance coverage, access, and individual response more than by which medication is theoretically better.